Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA.
J Neuropathol Exp Neurol. 2012 Jul;71(7):631-9. doi: 10.1097/NEN.0b013e31825c448a.
Cerebellar low-grade astrocytomas with a diffuse pattern of growth are uncommon, comprising World Health Organization (WHO) grade II diffuse astrocytomas (DA) and a minority of WHO grade I pilocytic astrocytomas (PA), so-called PA, "diffuse variant." Among 106 cerebellar low-grade astrocytomas (WHO grade I and II) operated on at the Mayo Clinic (1984-2010), we identified 19 such cases: 8 PA, "diffuse variant," 5 DA, and 6 that we were unable to classify further (low-grade astrocytomas, subtype indeterminate). We characterized these tumors using immunohistochemistry and currently available molecular markers (IDH1/2 mutations and BRAF mutation/fusion gene status) and investigated whether the markers could be used to aid the diagnostic process in combination with the clinical and pathologic features. KIAA1549-BRAF fusion was detected in 4 PA, "diffuse variant," 2 DA, and 2 low-grade astrocytomas, subtype indeterminate, indicating that these tumors were molecularly consistent with PA, the most common subtype of the series. A BRAF V600E mutation was detected in 1 PA, "diffuse variant" case; an IDH1 R132G mutation was found in 1 DA case. These results suggest that KIAA1549-BRAF fusion status and IDH1/2 and BRAF V600E mutational analyses may assist in the histologic classification of this diagnostically challenging group of tumors and result in a more accurate and objective combined molecular and histologic classification.
弥漫性生长的小脑低级别星形细胞瘤较为少见,包括世界卫生组织(WHO)分级 II 级弥漫性星形细胞瘤(DA)和少数 WHO 分级 I 级毛细胞星形细胞瘤(PA),即所谓的 PA,“弥漫性变异型”。在梅奥诊所(1984-2010 年)进行手术的 106 例小脑低级别星形细胞瘤(WHO 分级 I 和 II)中,我们确定了 19 例此类病例:8 例 PA,“弥漫性变异型”,5 例 DA,还有 6 例我们无法进一步分类(低级别星形细胞瘤,亚型不确定)。我们使用免疫组织化学和目前可用的分子标志物(IDH1/2 突变和 BRAF 突变/融合基因状态)对这些肿瘤进行了特征描述,并研究了这些标志物是否可以与临床和病理特征结合,用于辅助诊断过程。在 4 例 PA,“弥漫性变异型”,2 例 DA 和 2 例低级别星形细胞瘤,亚型不确定中检测到 KIAA1549-BRAF 融合,表明这些肿瘤在分子上与该系列中最常见的亚型 PA 一致。在 1 例 PA,“弥漫性变异型”病例中检测到 BRAF V600E 突变;在 1 例 DA 病例中发现 IDH1 R132G 突变。这些结果表明,KIAA1549-BRAF 融合状态以及 IDH1/2 和 BRAF V600E 突变分析可能有助于这组具有挑战性的肿瘤的组织学分类,并导致更准确和客观的联合分子和组织学分类。